title: [RU 486 (mifepristone) and therapeutic abortions in the second and third trimesters].
abstract: RU 486 activity for therapeutic pregnancy termination through prostaglandin was studied in a controlled survey including 50 patients, in the second and third trimester of pregnancy (in conformity with the French law). Patients were randomly divided into two groups. The first one was administered orally 200 mg of RU 486, 48 hours before the first Sulprostone injection. The control group did not receive any RU 486. The mean duration between prostaglandin administration and miscarriage was significantly shorter in the RU 486 group (13.16 hours), than in the control group (23.16 hours). Women with RU 486 treatment needed less prostaglandin doses and, above all, had less prostaglandin secondary effects than the patients in the control group.
authors.affiliation: Service de Gynécologie-Obstétrique, Hôpital Antoine-Béclère, Clamart.
authors.forename: J C
authors.initials: JC
authors.lastname: Pons
authors.forename: S
authors.initials: S
authors.lastname: Rais
authors.forename: P
authors.initials: P
authors.lastname: Diochin
authors.forename: R
authors.initials: R
authors.lastname: Frydman
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use*; D000032:Abortion, Therapeutic / Q000379:methods*; D000284:Administration, Oral; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010298:Parity; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D015735:Mifepristone; C016767:sulprostone; D015232:Dinoprostone
vernacular_title: RU 486 (mifépristone) et interruption volontaire de grossesse pour motif thérapeutique au deuxième et troisième trimestre.